Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study

PURPOSE: The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially unresectable hepatocellular carcinoma (uHCC) harbo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Song, Wu, Zhiqiang, Shi, Feng, Mai, Qicong, Wang, Liguang, Wang, Fan, Zhuang, Wenquan, Chen, Xiaoming, Chen, Huanwei, Xu, Bo, Lai, Jiaming, Guo, Wenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293824/
https://www.ncbi.nlm.nih.gov/pubmed/34453221
http://dx.doi.org/10.1007/s00432-021-03767-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293824/
https://www.ncbi.nlm.nih.gov/pubmed/34453221
http://dx.doi.org/10.1007/s00432-021-03767-4

Ejemplares similares